Skip to main
GMED
GMED logo

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. stands to benefit from several potential upside drivers, notably faster growth in the spine market and stronger sales in its Enabling Technologies segment, which could enhance overall margins. The company is currently trading below historical valuation levels, while demonstrating impressive free cash flow growth with an 8% free cash flow yield, indicating a favorable risk/reward scenario. Despite recent revenue results slightly missing consensus expectations, strong profit potential remains, suggesting that the company may see continued financial improvement in the coming years.

Bears say

Globus Medical Inc faces several challenges that contribute to a negative outlook on its stock, including anticipated slower growth in the spine market and revenue dis-synergies from the recent NuVasive merger. The company's reliance on musculoskeletal solutions, which generates the majority of its revenue, may be hindered by factors such as lower-than-expected sales in its Enabling Technologies segment and increased competitive pressures following industry restructuring. Additionally, concerns regarding potential declines in operating margins and slower expansion into new market areas could further exacerbate financial performance issues.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.